cilostazol has been researched along with Acute Ischemic Stroke in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared the risk of recurrent ischemic stroke, vascular events, and major bleeding between DAPT with cilostazol plus aspirin or clopidogrel and aspirin or clopidogrel alone in patients with ischemic stroke between 8 and 180 days before starting trial treatment and ECAS or without arterial stenosis." | 9.69 | Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial. ( Hoshino, H; Kimura, K; Kitagawa, K; Minematsu, K; Okamura, S; Omae, K; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2023) |
| "In the Cilostazol Stroke Prevention Study combination trial, patients with high-risk, non-cardioembolic ischemic stroke between 8 and 180 days after onset treated with aspirin or clopidogrel alone were recruited and randomly assigned to receive either monotherapy or dual antiplatelet therapy (DAPT) using cilostazol and followed up for 0." | 9.69 | Sex Difference in the Impact of Dual Antiplatelet Therapy using Cilostazol for Secondary Stroke Prevention: A Sub-Analysis of CSPS.com. ( Hoshino, H; Kimura, K; Minematsu, K; Omae, K; Origasa, H; Takahashi, K; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2023) |
| " Patients with diagnosis codes for ischemic stroke without cardiac disease were included and divided into two groups, those receiving cilostazol and those receiving clopidogrel." | 8.31 | Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke. ( Je, NK; Lee, YJ, 2023) |
| "Cilostazol is a PDE3 (phosphodiesterase III) inhibitor with a long track record of safety that is Food and Drug Administration and European Medicines Agency approved for the treatment of claudication in patients with peripheral arterial disease." | 6.72 | Cilostazol for Secondary Stroke Prevention: History, Evidence, Limitations, and Possibilities. ( de Havenon, A; Elm, JJ; Johnston, KC; Johnston, SC; Lansberg, MG; Madsen, TE; Sheth, KN; Shoamanesh, A; Toyoda, K; Turan, TN; Wardlaw, JM; Williams, OA, 2021) |
| "We compared the risk of recurrent ischemic stroke, vascular events, and major bleeding between DAPT with cilostazol plus aspirin or clopidogrel and aspirin or clopidogrel alone in patients with ischemic stroke between 8 and 180 days before starting trial treatment and ECAS or without arterial stenosis." | 5.69 | Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial. ( Hoshino, H; Kimura, K; Kitagawa, K; Minematsu, K; Okamura, S; Omae, K; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2023) |
| "In the Cilostazol Stroke Prevention Study combination trial, patients with high-risk, non-cardioembolic ischemic stroke between 8 and 180 days after onset treated with aspirin or clopidogrel alone were recruited and randomly assigned to receive either monotherapy or dual antiplatelet therapy (DAPT) using cilostazol and followed up for 0." | 5.69 | Sex Difference in the Impact of Dual Antiplatelet Therapy using Cilostazol for Secondary Stroke Prevention: A Sub-Analysis of CSPS.com. ( Hoshino, H; Kimura, K; Minematsu, K; Omae, K; Origasa, H; Takahashi, K; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2023) |
| "Although dual antiplatelet therapy (DAPT) with aspirin and clopidogrel reduces the recurrence of ischemic stroke while significantly increasing the bleeding events compared with monotherapy, the CSPS." | 5.41 | Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial. ( Hoshino, H; Houkin, K; Ishida, N; Isobe, M; Kimura, K; Matsumoto, M; Minematsu, K; Naritomi, H; Okada, Y; Omae, K; Origasa, H; Sakai, N; Tanaka, K; Terayama, Y; Tomimoto, H; Tominaga, T; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T; Yasuda, S, 2021) |
| " Search terms included ischemic stroke, aspirin, clopidogrel, dipyridamole, ticagrelor, cilostazol, prasugrel, glycoprotein IIb/IIIa inhibitors." | 5.22 | Antiplatelet Use in Ischemic Stroke. ( Ali, A; Baig, S; Bell, SM; Kamarova, M; Majid, A; Monks, K; Patel, H; Redgrave, J; Wasay, M, 2022) |
| " Cilostazol proved to be the most efficacious in reducing stroke recurrence and the risk of bleeding (RR = 0." | 5.22 | Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials. ( Bálint, A; El Abdallaoui, OEA; Komócsi, A; Kupó, P; Szapáry, L; Szapáry, LB; Tornyos, D, 2022) |
| " Randomized clinical trials that compared cilostazol to aspirin and reported the endpoints of ischemic stroke, intracranial hemorrhage and any bleeding were included." | 5.12 | Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis. ( Barrett, KM; Brott, TG; Ertekin-Taner, N; Gopal, N; Lin, MP; Meschia, JF; Ross, OA, 2021) |
| "Continuous treatment of cilostazol in patients with HD with PAD significantly decreases the risk of ED visits, hemorrhagic stroke, and cardiovascular events and improves ED visit-free and cardiovascular event-free rates during long-term follow-up." | 4.31 | Long-Term Effectiveness of Cilostazol in Patients with Hemodialysis with Peripheral Artery Disease. ( Chen, YY; Kao, ZK; Lin, CH; Wu, CK; Yang, YB; Yar, N, 2023) |
| "Patients who participated in the Acute Aspirin Plus Cilostazol Dual Therapy for Non-cardiogenic Stroke Patients Within 48 Hours of Symptom Onset (ADS) trial were included in this study." | 4.31 | Persistent High Pulse Pressure in Acute Non-Cardiogenic Ischemic Stroke as a Predictor of Neurological Deterioration and Recurrence of Ischemic Stroke: ADS Post-Hoc Analysis. ( Aoki, J; Fujimoto, S; Kimura, K; Matsuzono, K; Ozawa, T, 2023) |
| " Patients with diagnosis codes for ischemic stroke without cardiac disease were included and divided into two groups, those receiving cilostazol and those receiving clopidogrel." | 4.31 | Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke. ( Je, NK; Lee, YJ, 2023) |
| "Cilostazol is a PDE3 (phosphodiesterase III) inhibitor with a long track record of safety that is Food and Drug Administration and European Medicines Agency approved for the treatment of claudication in patients with peripheral arterial disease." | 2.72 | Cilostazol for Secondary Stroke Prevention: History, Evidence, Limitations, and Possibilities. ( de Havenon, A; Elm, JJ; Johnston, KC; Johnston, SC; Lansberg, MG; Madsen, TE; Sheth, KN; Shoamanesh, A; Toyoda, K; Turan, TN; Wardlaw, JM; Williams, OA, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 13 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Havenon, A | 1 |
| Sheth, KN | 1 |
| Madsen, TE | 1 |
| Johnston, KC | 1 |
| Turan, TN | 1 |
| Toyoda, K | 4 |
| Elm, JJ | 1 |
| Wardlaw, JM | 1 |
| Johnston, SC | 1 |
| Williams, OA | 1 |
| Shoamanesh, A | 1 |
| Lansberg, MG | 1 |
| Kamarova, M | 1 |
| Baig, S | 1 |
| Patel, H | 1 |
| Monks, K | 1 |
| Wasay, M | 1 |
| Ali, A | 1 |
| Redgrave, J | 1 |
| Majid, A | 1 |
| Bell, SM | 1 |
| Shah, J | 1 |
| Liu, S | 1 |
| Yu, W | 1 |
| Shirai, Y | 1 |
| Toi, S | 1 |
| Adachi, U | 1 |
| Tsutsumi, Y | 1 |
| Kitagawa, K | 2 |
| Uchiyama, S | 3 |
| Okamura, S | 1 |
| Omae, K | 3 |
| Hoshino, H | 3 |
| Kimura, K | 4 |
| Minematsu, K | 3 |
| Yamaguchi, T | 3 |
| Tornyos, D | 1 |
| Komócsi, A | 1 |
| Bálint, A | 1 |
| Kupó, P | 1 |
| El Abdallaoui, OEA | 1 |
| Szapáry, L | 1 |
| Szapáry, LB | 1 |
| Takahashi, K | 1 |
| Yamaguchi, K | 2 |
| Origasa, H | 2 |
| Wu, CK | 1 |
| Lin, CH | 1 |
| Yar, N | 1 |
| Kao, ZK | 1 |
| Yang, YB | 1 |
| Chen, YY | 1 |
| Liu, H | 1 |
| Shao, T | 1 |
| Yang, T | 1 |
| Li, D | 1 |
| Wang, H | 1 |
| Cheng, Y | 1 |
| Zhang, T | 1 |
| Zhang, J | 1 |
| Ozawa, T | 1 |
| Fujimoto, S | 1 |
| Aoki, J | 1 |
| Matsuzono, K | 1 |
| Lee, YJ | 1 |
| Je, NK | 1 |
| Lin, MP | 1 |
| Meschia, JF | 1 |
| Gopal, N | 1 |
| Barrett, KM | 1 |
| Ross, OA | 1 |
| Ertekin-Taner, N | 1 |
| Brott, TG | 1 |
| Ishida, N | 1 |
| Sakai, N | 1 |
| Okada, Y | 1 |
| Tanaka, K | 1 |
| Naritomi, H | 1 |
| Houkin, K | 1 |
| Isobe, M | 1 |
| Matsumoto, M | 1 |
| Tominaga, T | 1 |
| Tomimoto, H | 1 |
| Terayama, Y | 1 |
| Yasuda, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cilostazol Stroke Prevention Study for Antiplatelet Combination[NCT01995370] | Phase 4 | 1,884 participants (Actual) | Interventional | 2013-12-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for cilostazol and Acute Ischemic Stroke
| Article | Year |
|---|---|
Cilostazol for Secondary Stroke Prevention: History, Evidence, Limitations, and Possibilities.
Topics: Cilostazol; Evidence-Based Medicine; Humans; Ischemic Stroke; Phosphodiesterase 3 Inhibitors; Second | 2021 |
Antiplatelet Use in Ischemic Stroke.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Stroke; Platelet Aggre | 2022 |
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; | 2022 |
Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials.
Topics: Aspirin; Cilostazol; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic S | 2022 |
Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis.
Topics: Aged; Anti-Inflammatory Agents; Aspirin; Cilostazol; Female; Humans; Intracranial Hemorrhages; Ische | 2021 |
4 trials available for cilostazol and Acute Ischemic Stroke
| Article | Year |
|---|---|
Cilostazol improves endothelial function in patients with ischemic stroke: A randomized controlled single-center study with flow-mediated dilation technique.
Topics: Brain Ischemia; Cilostazol; Dilatation; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; St | 2022 |
Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Clopidogrel; Constriction, Pathologic; Drug Therapy, Combi | 2023 |
Sex Difference in the Impact of Dual Antiplatelet Therapy using Cilostazol for Secondary Stroke Prevention: A Sub-Analysis of CSPS.com.
Topics: Cilostazol; Drug Therapy, Combination; Female; Humans; Ischemic Stroke; Male; Platelet Aggregation I | 2023 |
Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial.
Topics: Aged; Aspirin; Cerebral Hemorrhage; Cilostazol; Clopidogrel; Drug Therapy, Combination; Dual Anti-Pl | 2021 |
4 other studies available for cilostazol and Acute Ischemic Stroke
| Article | Year |
|---|---|
Long-Term Effectiveness of Cilostazol in Patients with Hemodialysis with Peripheral Artery Disease.
Topics: Adult; Cilostazol; Hemorrhagic Stroke; Humans; Ischemic Stroke; Peripheral Arterial Disease; Platele | 2023 |
Comparison of Cilostazol versus Clopidogrel in Addition to Aspirin in Patients with Ischemic Stroke who Underwent Intracranial or Extracranial Artery Stent Implantation.
Topics: Arteries; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic | 2023 |
Persistent High Pulse Pressure in Acute Non-Cardiogenic Ischemic Stroke as a Predictor of Neurological Deterioration and Recurrence of Ischemic Stroke: ADS Post-Hoc Analysis.
Topics: Blood Pressure; Cilostazol; Humans; Ischemic Attack, Transient; Ischemic Stroke; Recurrence; Stroke | 2023 |
Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke.
Topics: Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Hemorrhagi | 2023 |